Despite the barriers to biosimilar development, several pharmaceutical organizations are fully committed to their biosimilar future. Over the course of the next several months, BR&R will highlight some of these intriguing pipeline portfolios. We’re kicking it off in this post with Sandoz’s biosimilar pipeline; the company just announced a much broader pipeline initiative. Whereas some … Continue reading Sandoz’s Wide Biosimilar Pipeline Getting Much Wider